Is American Tower Stock Undervalued?
The market action of late has been nothing short of…
Sell
42
BMED Quote, Financials, Valuation and Earnings
Last price:
$25.34
Seasonality move
:
-1.48%
Day range:
$25.34 - $25.37
52-week range:
$23.99 - $26.68
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
291
Avg. volume:
--
1-year change:
2.07%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BMED
iShares Health Innovation Active ETF
|
-- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- |
|
LGHT
Langar Global HealthTech ETF
|
-- | -- | -- | -- | -- |
|
MNTL
Tema Neuroscience and Mental Health ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BMED
iShares Health Innovation Active ETF
|
$25.37 | -- | -- | -- | $0.01 | 0% | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
$51.91 | -- | -- | -- | $0.33 | 5.43% | -- |
|
LGHT
Langar Global HealthTech ETF
|
$10.51 | -- | -- | -- | $0.00 | 0% | -- |
|
MNTL
Tema Neuroscience and Mental Health ETF
|
$24.67 | -- | -- | -- | $0.26 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BMED
iShares Health Innovation Active ETF
|
-- | 1.140 | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | 0.988 | -- | -- |
|
LGHT
Langar Global HealthTech ETF
|
-- | 0.000 | -- | -- |
|
MNTL
Tema Neuroscience and Mental Health ETF
|
-- | 0.000 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BMED
iShares Health Innovation Active ETF
|
-- | -- | -- | -- | -- | -- |
|
JDOC
JPMorgan Healthcare Leaders ETF
|
-- | -- | -- | -- | -- | -- |
|
LGHT
Langar Global HealthTech ETF
|
-- | -- | -- | -- | -- | -- |
|
MNTL
Tema Neuroscience and Mental Health ETF
|
-- | -- | -- | -- | -- | -- |
iShares Health Innovation Active ETF vs. Competitors
-
Which has Higher Returns BMED or JDOC?
JPMorgan Healthcare Leaders ETF has a net margin of -- compared to iShares Health Innovation Active ETF's net margin of --. iShares Health Innovation Active ETF's return on equity of -- beat JPMorgan Healthcare Leaders ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BMEDiShares Health Innovation Active ETF-- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- -
What do Analysts Say About BMED or JDOC?
iShares Health Innovation Active ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand JPMorgan Healthcare Leaders ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Health Innovation Active ETF has higher upside potential than JPMorgan Healthcare Leaders ETF, analysts believe iShares Health Innovation Active ETF is more attractive than JPMorgan Healthcare Leaders ETF.
Company Buy Ratings Hold Ratings Sell Ratings BMEDiShares Health Innovation Active ETF0 0 0 JDOCJPMorgan Healthcare Leaders ETF0 0 0 -
Is BMED or JDOC More Risky?
iShares Health Innovation Active ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison JPMorgan Healthcare Leaders ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BMED or JDOC?
iShares Health Innovation Active ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0%. JPMorgan Healthcare Leaders ETF offers a yield of 5.43% to investors and pays a quarterly dividend of $0.33 per share. iShares Health Innovation Active ETF pays -- of its earnings as a dividend. JPMorgan Healthcare Leaders ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMED or JDOC?
iShares Health Innovation Active ETF quarterly revenues are --, which are smaller than JPMorgan Healthcare Leaders ETF quarterly revenues of --. iShares Health Innovation Active ETF's net income of -- is lower than JPMorgan Healthcare Leaders ETF's net income of --. Notably, iShares Health Innovation Active ETF's price-to-earnings ratio is -- while JPMorgan Healthcare Leaders ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Health Innovation Active ETF is -- versus -- for JPMorgan Healthcare Leaders ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMEDiShares Health Innovation Active ETF-- -- -- -- JDOCJPMorgan Healthcare Leaders ETF-- -- -- --
-
Which has Higher Returns BMED or LGHT?
Langar Global HealthTech ETF has a net margin of -- compared to iShares Health Innovation Active ETF's net margin of --. iShares Health Innovation Active ETF's return on equity of -- beat Langar Global HealthTech ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BMEDiShares Health Innovation Active ETF-- -- -- LGHTLangar Global HealthTech ETF-- -- -- -
What do Analysts Say About BMED or LGHT?
iShares Health Innovation Active ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Langar Global HealthTech ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Health Innovation Active ETF has higher upside potential than Langar Global HealthTech ETF, analysts believe iShares Health Innovation Active ETF is more attractive than Langar Global HealthTech ETF.
Company Buy Ratings Hold Ratings Sell Ratings BMEDiShares Health Innovation Active ETF0 0 0 LGHTLangar Global HealthTech ETF0 0 0 -
Is BMED or LGHT More Risky?
iShares Health Innovation Active ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Langar Global HealthTech ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BMED or LGHT?
iShares Health Innovation Active ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0%. Langar Global HealthTech ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iShares Health Innovation Active ETF pays -- of its earnings as a dividend. Langar Global HealthTech ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMED or LGHT?
iShares Health Innovation Active ETF quarterly revenues are --, which are smaller than Langar Global HealthTech ETF quarterly revenues of --. iShares Health Innovation Active ETF's net income of -- is lower than Langar Global HealthTech ETF's net income of --. Notably, iShares Health Innovation Active ETF's price-to-earnings ratio is -- while Langar Global HealthTech ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Health Innovation Active ETF is -- versus -- for Langar Global HealthTech ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMEDiShares Health Innovation Active ETF-- -- -- -- LGHTLangar Global HealthTech ETF-- -- -- --
-
Which has Higher Returns BMED or MNTL?
Tema Neuroscience and Mental Health ETF has a net margin of -- compared to iShares Health Innovation Active ETF's net margin of --. iShares Health Innovation Active ETF's return on equity of -- beat Tema Neuroscience and Mental Health ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BMEDiShares Health Innovation Active ETF-- -- -- MNTLTema Neuroscience and Mental Health ETF-- -- -- -
What do Analysts Say About BMED or MNTL?
iShares Health Innovation Active ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Tema Neuroscience and Mental Health ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that iShares Health Innovation Active ETF has higher upside potential than Tema Neuroscience and Mental Health ETF, analysts believe iShares Health Innovation Active ETF is more attractive than Tema Neuroscience and Mental Health ETF.
Company Buy Ratings Hold Ratings Sell Ratings BMEDiShares Health Innovation Active ETF0 0 0 MNTLTema Neuroscience and Mental Health ETF0 0 0 -
Is BMED or MNTL More Risky?
iShares Health Innovation Active ETF has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Tema Neuroscience and Mental Health ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BMED or MNTL?
iShares Health Innovation Active ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 0%. Tema Neuroscience and Mental Health ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.26 per share. iShares Health Innovation Active ETF pays -- of its earnings as a dividend. Tema Neuroscience and Mental Health ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BMED or MNTL?
iShares Health Innovation Active ETF quarterly revenues are --, which are smaller than Tema Neuroscience and Mental Health ETF quarterly revenues of --. iShares Health Innovation Active ETF's net income of -- is lower than Tema Neuroscience and Mental Health ETF's net income of --. Notably, iShares Health Innovation Active ETF's price-to-earnings ratio is -- while Tema Neuroscience and Mental Health ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iShares Health Innovation Active ETF is -- versus -- for Tema Neuroscience and Mental Health ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BMEDiShares Health Innovation Active ETF-- -- -- -- MNTLTema Neuroscience and Mental Health ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock Overvalued?
The semiconductor company Broadcom Inc. (NASDAQ:AVGO) is having a stellar…
4 Top Dividend Stocks to Buy Now
If you’re looking for steady income, dividend stocks are a…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 39x
Sell
47
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 114x
Sell
39
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
87
CEG alert for Jan 11
Constellation Energy [CEG] is up 25.15% over the past day.
Sell
1
MCY alert for Jan 11
Mercury General [MCY] is down 19.87% over the past day.
Buy
84
ATZAF alert for Jan 11
Aritzia [ATZAF] is up 17.63% over the past day.
